Apimeds Pharmaceuticals US, Inc. has 5 Schedule 13D or 13G filings on record since 2026-01-26. 2 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Inscobee Inc. | 34.3% | 2,099,747 | SCHEDULE 13D/A, 2026-05-07 | 2026-05-07 |
| Ayrton Capital LLC | 9.99% | 1,397,021 | SCHEDULE 13G, 2026-02-11 | 2025-12-31 |
Purpose of Transaction (Item 4)
Inscobee Inc.
The information set forth in Item 3 of the Schedule 13D is incorporated herein by reference. The Reporting Persons acquired the securities of the Issuer for investment purposes. As previously disclosed, the Reporting Persons engaged in discussions and disputes with the Issuer and certain other parties in connection with, among other things, the Merger Agreement, the Support & Lock-Up Agreement, the Voting Agreements and related transactions. On April 24, 2026, the Reporting Persons and certain other parties entered into a Settlement Agreement (the "Settlement Agreement"), as disclosed in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 4, 2026 (the "Current Report"), pursuant to which the parties agreed to resolve certain disputes relating to the Issuer, the Merger and related transactions. In connection with the Settlement Agreement, the Reporting Persons and certain other parties also entered into (i) a Side Letter Agreement (the "Side Letter") and (ii) a Forbearance Agreement (the "Forbearance Agreement," and together with the Settlement Agreement and Side Letter, the "Settlement Documents"), each as described in the Current Report. The Settlement Documents provide for, among other things: - the resolution of disputes among the parties relating to the Merger and related transactions; - the dismissal of certain litigation and release of claims related to the Merger Agreement, including the dismissal by Erik Emerson of …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-05-07; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-01-26 | Inscobee Inc. | 34.3% | SCHEDULE 13D/A |
| 2026-02-11 | Ayrton Capital LLC | 9.99% | SCHEDULE 13G |
| 2026-03-20 | Inscobee Inc. | 34.3% | SCHEDULE 13D/A |
| 2026-03-30 | Inscobee Inc. | 34.3% | SCHEDULE 13D/A |
| 2026-05-07 | Inscobee Inc. | 34.3% | SCHEDULE 13D/A |
Tools for this story
Each opens in a new tab, filled in for Apimeds Pharmaceuticals US, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.